Vipivotidetetraxetan Ligand-Linker Conjugate

Vipivotide tetraxetan Ligand-Linker Conjugate (PSMA-617 Ligand-Linker Conjugate) is a complex composed of pharmacophore group Glutamate-urea-Lysine peptide coupling linker, which can be used to synthesize Vipivotide tetraxetan (PSMA-617) . Glutamate-urea-Lysine selectively binds to prostate-specific membrane antigen (PSMA) [1].

1703768-74-4

PSMA-617 Ligand-Linker Conjugate

12352203

H302, H315, H319, H335

ADC Linker

Antibody-drug Conjugate/ADC Related

Cancer-programmed cell death

Cancer

99.89

DMSO : 125 mg/mL (ultrasonic)

O=C(O)[C@H](CCCCNC([C@H](CC1=CC=C2C=CC=CC2=C1)NC([C@H]3CC[C@H](CN)CC3)=O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O

C33H45N5O9

655.74

H302, H315, H319, H335

[1]Benešová M, et al. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile. Mol Pharm. 2018 Mar 5;15 (3) :934-946.

Blue Ice

-20°C, 3 years (Powder)

http://file.medchemexpress.com/batch_PDF/HY-43869/Vipivotide-tetraxetan-Ligand-Linker-Conjugate-SDS-MedChemExpress.pdf

ADC Related

No Development Reported

Non-cleavable Linker